THE WOODLANDS, Texas, Nov. 17, 2004 (PRIMEZONE) -- Power3 Medical Products, Inc. (OTCBB:PWRM) announces the appointment of Dr. Alan Hollingsworth to the Company's Scientific Advisory Board. The appointment is a result of a recent research agreement between Power3 Medical and Mercy Women's Center in Oklahoma City, Oklahoma on the identification of protein biomarkers for the early detection of breast cancer through blood serum and nipple aspirate fluid. The biomarkers being studied have been obtained through a licensing agreement with leading cancer research center where the research originated.
Dr. Hollingsworth is currently the Medical Director at Mercy Women's Center in Oklahoma City. For more than a decade, and long before there was much interest in finding a blood test to screen for early breast cancer, Dr. Hollingsworth has been pursuing this research agenda. During the past two years, Mercy Women's Center and Breast MRI of Oklahoma have been collecting blood samples from women undergoing MRI of the breast. This database now accounts for the largest collection of samples tied to MRI results in the country.
Steve Rash, Chief Executive Officer of Power3 Medical states, "Mercy Women's Center has shown remarkable dedication to finding an early detection test for breast cancer under Dr. Hollingsworth's guidance. Dr. Hollingsworth's vast experience and commitment in the field of breast cancer research is a tremendous addition to Power3's Scientific Advisory Board."
Dr. Alan Hollingsworth responds, "I am very grateful for the opportunity to serve on Power3's Scientific Advisory Board. It is very exciting to work with their innovative NAF test which, if successful in detecting breast cancer in its extremely early stages, will greatly empower us to fight this disease."
About Power3 Medical Products, Inc.
Power3 Medical Products, Inc. is a leading proteomics company engaged in the discovery of protein footprints, pathways, and mechanisms of diseases. The Company's patent pending technologies are being used to develop screening and diagnostic tests for the early detection and treatment of disease. The Company's identified protein biomarkers, drug targets, and diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease.
Safe Harbor Statement
All statements other than statements of historical fact included in this press release are "forward-looking statements." The forward-looking statements, including statements about the Company's future expectations, including future revenues and earnings, and all other forward-looking statements (i.e., future operational results and sales) are subject to assumptions and beliefs based on current information known to the Company and factors that are subject to uncertainties, risk and other influences, which are outside the Company's control, and may yield results differing materially from those anticipated.